Identification and characterization of nonapeptide targeting a human B cell lymphoma, Raji

International Immunopharmacology

Volumn 8, Issue 6, 2008, Pages 852-858

  Choi, Jin Huk ^a   Lee, Woon Kyu ^b   Han, Seung Hyun ^c,d   Ha, Seckho ^e   Ahn, Sung Min ^a   Kang, Jae Seong ^a   Choi, Yun Jaie ^a   Yun, Cheol Heui ^a  

^a Seoul National University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d International Vaccine Institute   (South Korea)

^e 13F KOTECH Bldg 701 7   (South Korea)

Author keywords

B cell lymphoma; Phage display; Raji; Targeting peptide

Indexed keywords

CYSTEINYLTHREONYLLEUCYLPROLYLHISTIDYLLEUCYLLYSYLMETHIONYLCYSTEINE; PEPTIDE;

AMINO ACID SEQUENCE; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BINDING AFFINITY; BINDING ASSAY; BIOTINYLATION; CONTROLLED STUDY; DRUG TARGETING; FLOW CYTOMETRY; HEAVY CHAIN; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPRECIPITATION; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MONONUCLEAR CELL; PEPTIDE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAJI CELL;

BURKITT LYMPHOMA; CELL LINE, TUMOR; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LIGANDS; OLIGOPEPTIDES; PEPTIDE LIBRARY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 43049135131     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.01.037     Document Type: Article

References (25)

1. Favrot M.C., Maritaz O., Suzuki T., Cooper M., Philip I., Philip T., et al. EBV-negative and -positive Burkitt cell lines variably express receptors for B-cell activation and differentiation. Int J Cancer 38 6 (1986) 901-906
2. Goossens T., Klein U., and Kuppers R. Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease. Proc Natl Acad Sci U S A 95 5 (1998) 2463-2468
3. Kelley M.J., and Mulshine J.L. Anticancer antibodies for lung cancer. J Clin Oncol 12 11 (1994) 2519-2520
4. Weiner G.J., and Link B.K. Monoclonal antibody therapy of B cell lymphoma. Expert Opin Biol Ther 4 3 (2004) 375-385
5. Hatakeyama H., Akita H., Ishida E., Hashimoto K., Kobayashi H., Aoki T., et al. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int J Pharm 342 1-2 (2007) 194-200
6. Maruyama K. PEG-immunoliposome. Biosci Rep 22 2 (2002) 251-266
7. Hajitou A., Trepel M., Lilley C.E., Soghomonyan S., Alauddin M.M., Marini III F.C., et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 125 2 (2006) 385-398
8. Joyce J.A., Laakkonen P., Bernasconi M., Bergers G., Ruoslahti E., and Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4 5 (2003) 393-403
9. Kolonin M., Pasqualini R., and Arap W. Molecular addresses in blood vessels as targets for therapy. Curr Opin Chem Biol 5 3 (2001) 308-313
10. Arap W., Kolonin M.G., Trepel M., Lahdenranta J., Cardo-Vila M., Giordano R.J., et al. Steps toward mapping the human vasculature by phage display. Nat Med 8 2 (2002) 121-127
11. Pasqualini R., and Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 380 6572 (1996) 364-366
12. Balestrieri M.L., and Napoli C. Novel challenges in exploring peptide ligands and corresponding tissue-specific endothelial receptors. Eur J Cancer 43 8 (2007) 1242-1250
13. Hajitou A., Pasqualini R., and Arap W. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 16 3 (2006) 80-88
14. Trepel M., Arap W., and Pasqualini R. In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol 6 3 (2002) 399-404
15. Bakalova R., Ohba H., Zhelev Z., Kubo T., Fujii M., Ishikawa M., et al. Atypical protein-kinase Czeta, but neither conventional Ca2+-dependent protein-kinase C isoenzymes nor Ca2+-calmodulin, participates in regulation of telomerase activity in Burkitt's lymphoma cells. Cancer Chemother Pharmacol 54 2 (2004) 161-172
16. des Rieux A., Ragnarsson E.G., Gullberg E., Preat V., Schneider Y.J., and Artursson P. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur J Pharm Sci 25 4-5 (2005) 455-465
17. Ouzilou L., Caliot E., Pelletier I., Prevost M.C., Pringault E., and Colbere-Garapin F. Poliovirus transcytosis through M-like cells. J Gen Virol 83 Pt 9 (2002) 2177-2182
18. Kerneis S., Bogdanova A., Kraehenbuhl J.P., and Pringault E. Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria. Science 277 5328 (1997) 949-952
19. Lopes de Menezes D.E., Pilarski L.M., and Allen T.M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 58 15 (1998) 3320-3330
20. Lundberg B.B., Griffiths G., and Hansen H.J. Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells. J Control Release 94 1 (2004) 155-161
21. Maddipatla S., Hernandez-Ilizaliturri F.J., Knight J., and Czuczman M.S. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res 13 15 Pt 1 (2007) 4556-4564
22. Pagel J.M., Pantelias A., Hedin N., Wilbur S., Saganic L., Lin Y., et al. Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas. Cancer Res 67 12 (2007) 5921-5928
23. Yoshida S., Nakamura N., Sasaki Y., Yoshida S., Yasuda M., Sagara H., et al. Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype. Mod Pathol 18 3 (2005) 398-405
24. Wabl M.R., Jack H.M., von Borstel R.C., and Steinberg C.M. Scope of action of the immunoglobulin mutator system. Genome 31 1 (1989) 118-121
25. Vallera D.A., Todhunter D.A., Kuroki D.W., Shu Y., Sicheneder A., and Chen H. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res 11 10 (2005) 3879-3888